Glucagon-like peptide agonists (GLP-1s, like Ozempic, Wegovy, and Mounjaro) have been hailed as breakthroughs. From statins to Viagra, occasionally a drug development breakthrough occurs that is ...

Jo Varshney, PhD, DVM, discusses how artificial intelligence–powered simulations speed drug approvals and reduce clinical ...

With an AI-led platform for drug discovery and a growing global client base, Medvolt AI is emerging as one of India’s most ...

The discovery of GLP-1 and its role in regulating blood glucose was a major scientific breakthrough in diabetes research, yet turning this peptide hormone into an effective medication was no easy task ...

BUFFALO, N.Y. — University at Buffalo researcher Murali Ramanathan, PhD, has used artificial intelligence (AI) since its nascent days while exploring possible treatments for multiple sclerosis (MS) ...

The wide range of chromatographic techniques share one common aim: to separate a material into its components. A material, your sample, is dissolved in a solvent, called the mobile phase. This mixture ...

Ebrahimi is a scientific leader at GSK. Mrksich is the Henry Wade Rogers professor at Northwestern University, where he is developing the MegaMolecule technology for creating multifunctional ...

A stylized image of Max Barnhart sitting on a chair with his arm on a pillow, receiving an IV infusion. The background is a grid containing a microscope image of malaria parasites flanked on each side ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...